$GNPX
Genprex Inc

2023 Q3 Form 10-Q Financial Statement

#000143774923024247 Filed on August 21, 2023

View on sec.gov

Income Statement

Concept 2023 Q3 2023 Q2
Revenue $0.00 $0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $3.170M $4.050M
YoY Change 26.24% 66.56%
% of Gross Profit
Research & Development $4.617M $3.977M
YoY Change 28.48% 45.3%
% of Gross Profit
Depreciation & Amortization $3.724K $3.837K
YoY Change -40.17% -41.36%
% of Gross Profit
Operating Expenses $4.617M $3.977M
YoY Change 28.48% 45.3%
Operating Profit -$7.786M -$8.036M
YoY Change 27.42% 55.28%
Interest Expense $40.00K $60.00K
YoY Change 43.47% 945.3%
% of Operating Profit
Other Income/Expense, Net
YoY Change
Pretax Income -$7.750M -$7.980M
YoY Change 27.41% 54.37%
Income Tax
% Of Pretax Income
Net Earnings -$7.748M -$7.980M
YoY Change 27.38% 54.38%
Net Earnings / Revenue
Basic Earnings Per Share -$0.13 -$0.15
Diluted Earnings Per Share -$0.13 -$0.15
COMMON SHARES
Basic Shares Outstanding 59.41M 51.98M
Diluted Shares Outstanding

Balance Sheet

Concept 2023 Q3 2023 Q2
SHORT-TERM ASSETS
Cash & Short-Term Investments $11.71M $9.956M
YoY Change -54.11% -66.87%
Cash & Equivalents $11.71M $9.956M
Short-Term Investments
Other Short-Term Assets $1.150M $2.410M
YoY Change 51.86% 184.32%
Inventory
Prepaid Expenses
Receivables $0.00 $0.00
Other Receivables $0.00 $0.00
Total Short-Term Assets $12.86M $12.37M
YoY Change -51.13% -59.98%
LONG-TERM ASSETS
Property, Plant & Equipment $11.45K $15.18K
YoY Change -60.65% -57.04%
Goodwill
YoY Change
Intangibles $763.5K $741.7K
YoY Change 11.93% 11.36%
Long-Term Investments
YoY Change
Other Assets $3.775M $3.530M
YoY Change 4.62% -2.73%
Total Long-Term Assets $3.787M $3.545M
YoY Change 4.09% -3.26%
TOTAL ASSETS
Total Short-Term Assets $12.86M $12.37M
Total Long-Term Assets $3.787M $3.545M
Total Assets $16.64M $15.91M
YoY Change -44.42% -53.97%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $1.180M $1.498M
YoY Change 72.55% 119.22%
Accrued Expenses
YoY Change
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $4.338M $3.860M
YoY Change 76.54% 79.23%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00
YoY Change
Other Long-Term Liabilities
YoY Change
Total Long-Term Liabilities $0.00 $0.00
YoY Change
TOTAL LIABILITIES
Total Short-Term Liabilities $4.338M $3.860M
Total Long-Term Liabilities $0.00 $0.00
Total Liabilities $4.340M $3.860M
YoY Change 76.62% 79.23%
SHAREHOLDERS EQUITY
Retained Earnings -$127.8M -$120.0M
YoY Change 34.49% 34.98%
Common Stock $59.43K $51.98K
YoY Change 23.76% 8.52%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $12.31M $12.05M
YoY Change
Total Liabilities & Shareholders Equity $16.64M $15.91M
YoY Change -44.42% -53.97%

Cashflow Statement

Concept 2023 Q3 2023 Q2
OPERATING ACTIVITIES
Net Income -$7.748M -$7.980M
YoY Change 27.38% 54.38%
Depreciation, Depletion And Amortization $3.724K $3.837K
YoY Change -40.17% -41.36%
Cash From Operating Activities -$4.730M -$8.107M
YoY Change 3.48% 78.66%
INVESTING ACTIVITIES
Capital Expenditures $20.00K $20.00K
YoY Change -224.61% -191.53%
Acquisitions
YoY Change
Other Investing Activities
YoY Change
Cash From Investing Activities -$20.00K -$20.00K
YoY Change -162.02% -156.37%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 6.510M 0.000
YoY Change 371900.0%
NET CHANGE
Cash From Operating Activities -4.730M -8.107M
Cash From Investing Activities -20.00K -20.00K
Cash From Financing Activities 6.510M 0.000
Net Change In Cash 1.760M -8.127M
YoY Change -138.79% 80.51%
FREE CASH FLOW
Cash From Operating Activities -$4.730M -$8.107M
Capital Expenditures $20.00K $20.00K
Free Cash Flow -$4.750M -$8.127M
YoY Change 4.28% 79.96%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2023Q2 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2023Q2 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
dei Amendment Flag
AmendmentFlag
false
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q2
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2023
CY2023Q2 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
usd
CY2022Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
usd
CY2023Q2 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2022Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2023Q2 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000
CY2022Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000
CY2022Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2022Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2023Q2 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2022Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2023Q2 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
200000000
CY2022Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
200000000
CY2023Q2 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
51979078
CY2023Q2 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
51979078
CY2022Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
48105962
CY2022Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
48105962
CY2022Q4 us-gaap Cash Equivalents At Carrying Value
CashEquivalentsAtCarryingValue
0 usd
us-gaap Impairment Of Long Lived Assets Held For Use
ImpairmentOfLongLivedAssetsHeldForUse
0 usd
CY2022Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2022Q4 us-gaap Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1
ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
4.32
CY2021Q4 us-gaap Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1
ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
4.39
CY2023Q1 us-gaap Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1
ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
2.23
CY2022Q1 us-gaap Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1
ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
4.39
CY2023Q2 us-gaap Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1
ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
2.23
CY2022Q2 us-gaap Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1
ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
4.41
CY2023Q2 gnpx Class Of Warrant Or Right Exercisable Exercise Price
ClassOfWarrantOrRightExercisableExercisePrice
2.23
CY2022Q2 gnpx Class Of Warrant Or Right Exercisable Exercise Price
ClassOfWarrantOrRightExercisableExercisePrice
4.66
CY2023Q2 gnpx Class Of Warrant Or Right Issued In Period
ClassOfWarrantOrRightIssuedInPeriod
0
gnpx Class Of Warrant Or Right Issued In Period
ClassOfWarrantOrRightIssuedInPeriod
0
CY2022Q2 gnpx Class Of Warrant Or Right Issued In Period
ClassOfWarrantOrRightIssuedInPeriod
0
CY2023Q2 us-gaap Warrants And Rights Outstanding Term
WarrantsAndRightsOutstandingTerm
P5Y
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Expiration Period
SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod
P10Y
CY2022Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
3.08
CY2021Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
3.35
CY2023Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
3.07
CY2022Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
3.13
CY2023Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
3.06
CY2022Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
3.06
CY2023Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
3.16
CY2022Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
3.20
dei Document Type
DocumentType
10-Q
dei Document Quarterly Report
DocumentQuarterlyReport
true
dei Document Period End Date
DocumentPeriodEndDate
2023-06-30
dei Document Transition Report
DocumentTransitionReport
false
dei Entity File Number
EntityFileNumber
001-38244
dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
dei Entity Tax Identification Number
EntityTaxIdentificationNumber
90-0772347
dei Entity Address Address Line1
EntityAddressAddressLine1
3300 Bee Cave Road, #650-227
dei Entity Address City Or Town
EntityAddressCityOrTown
Austin
dei Entity Address State Or Province
EntityAddressStateOrProvince
TX
dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
78746
dei City Area Code
CityAreaCode
512
dei Local Phone Number
LocalPhoneNumber
537-7997
dei Security12b Title
Security12bTitle
Common Stock, par value $0.001 per share
dei Trading Symbol
TradingSymbol
GNPX
dei Security Exchange Name
SecurityExchangeName
NASDAQ
dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
dei Entity Small Business
EntitySmallBusiness
true
dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
true
dei Entity Ex Transition Period
EntityExTransitionPeriod
true
dei Entity Shell Company
EntityShellCompany
false
CY2023Q3 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
59409822
CY2023Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
9955684 usd
CY2022Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
20954069 usd
CY2023Q2 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
0 usd
CY2022Q4 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
34852 usd
CY2023Q2 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
2410425 usd
CY2022Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
484224 usd
CY2023Q2 us-gaap Assets Current
AssetsCurrent
12366109 usd
CY2022Q4 us-gaap Assets Current
AssetsCurrent
21473145 usd
CY2023Q2 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
15179 usd
CY2022Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
23032 usd
CY2023Q2 us-gaap Deposits Assets Noncurrent
DepositsAssetsNoncurrent
17154 usd
CY2022Q4 us-gaap Deposits Assets Noncurrent
DepositsAssetsNoncurrent
21818 usd
CY2023Q2 gnpx Research And Development Assets Noncurrent
ResearchAndDevelopmentAssetsNoncurrent
2770955 usd
CY2022Q4 gnpx Research And Development Assets Noncurrent
ResearchAndDevelopmentAssetsNoncurrent
2864937 usd
CY2023Q2 us-gaap Intangible Assets Net Excluding Goodwill
IntangibleAssetsNetExcludingGoodwill
741722 usd
CY2022Q4 us-gaap Intangible Assets Net Excluding Goodwill
IntangibleAssetsNetExcludingGoodwill
702095 usd
CY2023Q2 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
3529831 usd
CY2022Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
3588850 usd
CY2023Q2 us-gaap Assets
Assets
15911119 usd
CY2022Q4 us-gaap Assets
Assets
25085027 usd
CY2023Q2 us-gaap Accounts Payable And Accrued Liabilities Current
AccountsPayableAndAccruedLiabilitiesCurrent
1497979 usd
CY2022Q4 us-gaap Accounts Payable And Accrued Liabilities Current
AccountsPayableAndAccruedLiabilitiesCurrent
442925 usd
CY2023Q2 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
2362267 usd
CY2022Q4 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
2367362 usd
CY2023Q2 us-gaap Liabilities Current
LiabilitiesCurrent
3860246 usd
CY2022Q4 us-gaap Liabilities Current
LiabilitiesCurrent
2810287 usd
CY2023Q2 us-gaap Preferred Stock Value
PreferredStockValue
0 usd
CY2022Q4 us-gaap Preferred Stock Value
PreferredStockValue
0 usd
CY2023Q2 us-gaap Common Stock Value
CommonStockValue
51979 usd
CY2022Q4 us-gaap Common Stock Value
CommonStockValue
48106 usd
CY2023Q2 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
132009680 usd
CY2022Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
125054453 usd
CY2023Q2 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-120010786 usd
CY2022Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-102827819 usd
CY2023Q2 us-gaap Stockholders Equity
StockholdersEquity
12050873 usd
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
22274740 usd
CY2023Q2 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
15911119 usd
CY2022Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
25085027 usd
CY2023Q2 us-gaap Depreciation
Depreciation
3837 usd
CY2022Q2 us-gaap Depreciation
Depreciation
6544 usd
us-gaap Depreciation
Depreciation
7853 usd
us-gaap Depreciation
Depreciation
13274 usd
CY2023Q2 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
3976917 usd
CY2022Q2 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
2926927 usd
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
9287065 usd
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
4967153 usd
CY2023Q2 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
4054990 usd
CY2022Q2 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
2836916 usd
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
8012070 usd
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
6100656 usd
CY2023Q2 us-gaap Costs And Expenses
CostsAndExpenses
8035744 usd
CY2022Q2 us-gaap Costs And Expenses
CostsAndExpenses
5770387 usd
us-gaap Costs And Expenses
CostsAndExpenses
17306988 usd
us-gaap Costs And Expenses
CostsAndExpenses
11081083 usd
CY2023Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
-8035744 usd
CY2022Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
-5770387 usd
us-gaap Operating Income Loss
OperatingIncomeLoss
-17306988 usd
us-gaap Operating Income Loss
OperatingIncomeLoss
-11081083 usd
CY2023Q2 us-gaap Investment Income Interest
InvestmentIncomeInterest
55551 usd
CY2022Q2 us-gaap Investment Income Interest
InvestmentIncomeInterest
5744 usd
us-gaap Investment Income Interest
InvestmentIncomeInterest
124021 usd
us-gaap Investment Income Interest
InvestmentIncomeInterest
6623 usd
CY2023Q2 us-gaap Net Income Loss
NetIncomeLoss
-7980193 usd
CY2022Q2 us-gaap Net Income Loss
NetIncomeLoss
-5764643 usd
us-gaap Net Income Loss
NetIncomeLoss
-17182967 usd
us-gaap Net Income Loss
NetIncomeLoss
-11074460 usd
CY2023Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.15
CY2022Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.12
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.34
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.23
CY2023Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
51978968
CY2022Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
47893404
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
50732237
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
47886538
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
41276991 usd
CY2022Q1 us-gaap Stock Issued During Period Value Issued For Services
StockIssuedDuringPeriodValueIssuedForServices
17500 usd
CY2022Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
1039940 usd
CY2022Q1 us-gaap Net Income Loss
NetIncomeLoss
-5309817 usd
CY2022Q1 us-gaap Stockholders Equity
StockholdersEquity
37024614 usd
CY2022Q2 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
0 usd
CY2022Q2 us-gaap Stock Issued During Period Value Issued For Services
StockIssuedDuringPeriodValueIssuedForServices
17972 usd
CY2022Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
1133342 usd
CY2022Q2 us-gaap Net Income Loss
NetIncomeLoss
-5764643 usd
CY2022Q2 us-gaap Stockholders Equity
StockholdersEquity
32411285 usd
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
22274740 usd
CY2023Q1 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
4080780 usd
CY2023Q1 us-gaap Stock Issued During Period Value Issued For Services
StockIssuedDuringPeriodValueIssuedForServices
7950 usd
CY2023Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
1324165 usd
CY2023Q1 us-gaap Net Income Loss
NetIncomeLoss
-9202774 usd
CY2023Q1 us-gaap Stockholders Equity
StockholdersEquity
18484861 usd
CY2023Q2 us-gaap Stock Issued During Period Value Issued For Services
StockIssuedDuringPeriodValueIssuedForServices
4400 usd
CY2023Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
1541805 usd
CY2023Q2 us-gaap Net Income Loss
NetIncomeLoss
-7980193 usd
CY2023Q2 us-gaap Stockholders Equity
StockholdersEquity
12050873 usd
us-gaap Net Income Loss
NetIncomeLoss
-17182967 usd
us-gaap Net Income Loss
NetIncomeLoss
-11074460 usd
us-gaap Depreciation
Depreciation
7853 usd
us-gaap Depreciation
Depreciation
13274 usd
us-gaap Share Based Compensation
ShareBasedCompensation
2878320 usd
us-gaap Share Based Compensation
ShareBasedCompensation
2208754 usd
us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
-34852 usd
us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
-0 usd
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
1921536 usd
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
337762 usd
gnpx Increase Decrease In Research And Development Supplies
IncreaseDecreaseInResearchAndDevelopmentSupplies
-93982 usd
gnpx Increase Decrease In Research And Development Supplies
IncreaseDecreaseInResearchAndDevelopmentSupplies
-69485 usd
us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
1055054 usd
us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
-289872 usd
us-gaap Increase Decrease In Other Current Liabilities
IncreaseDecreaseInOtherCurrentLiabilities
-5096 usd
us-gaap Increase Decrease In Other Current Liabilities
IncreaseDecreaseInOtherCurrentLiabilities
858415 usd
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-15039538 usd
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-8552166 usd
us-gaap Payments To Acquire Intangible Assets
PaymentsToAcquireIntangibleAssets
39627 usd
us-gaap Payments To Acquire Intangible Assets
PaymentsToAcquireIntangibleAssets
23689 usd
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-39627 usd
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-23689 usd
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
4080780 usd
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
0 usd
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
4080780 usd
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
0 usd
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-10998385 usd
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-8575855 usd
CY2022Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
20954069 usd
CY2021Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
38628876 usd
CY2023Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
9955684 usd
CY2022Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
30053021 usd
us-gaap Use Of Estimates
UseOfEstimates
<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;"><span style="text-decoration: underline; "><i>Use of Estimates</i></span></p> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt;"> </p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;">The preparation of our unaudited condensed financial statements in conformity with U.S. GAAP requires us to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the unaudited condensed financial statements and the reported amounts of expenses during the reporting period. Actual results could differ from those estimates.</p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;"> </p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;"></p>
CY2023Q2 us-gaap Cash Uninsured Amount
CashUninsuredAmount
9718036 usd
CY2022Q4 us-gaap Cash Uninsured Amount
CashUninsuredAmount
20679538 usd
CY2023Q2 us-gaap Cash Equivalents At Carrying Value
CashEquivalentsAtCarryingValue
0 usd
CY2022Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
487604
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
2892166
CY2023Q2 gnpx Research And Development Assets Current
ResearchAndDevelopmentAssetsCurrent
2770955 usd
CY2022Q4 gnpx Research And Development Assets Current
ResearchAndDevelopmentAssetsCurrent
2864937 usd
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod
17500
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice
2.00
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P6Y7M13D
CY2022 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P7Y29D
CY2022 us-gaap Impairment Of Long Lived Assets Held For Use
ImpairmentOfLongLivedAssetsHeldForUse
0 usd
gnpx Stock Issued During Period Shares Exercise Of Cashless Warrants
StockIssuedDuringPeriodSharesExerciseOfCashlessWarrants
13643
CY2018Q2 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000
CY2018Q2 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2018Q2 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
200000000
CY2018Q2 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2023Q2 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
51979078
CY2023Q2 us-gaap Defined Contribution Plan Cost Recognized
DefinedContributionPlanCostRecognized
27758 usd
us-gaap Defined Contribution Plan Cost Recognized
DefinedContributionPlanCostRecognized
90806 usd
CY2022Q2 us-gaap Defined Contribution Plan Cost Recognized
DefinedContributionPlanCostRecognized
22048 usd
us-gaap Defined Contribution Plan Cost Recognized
DefinedContributionPlanCostRecognized
25752 usd
CY2022Q4 us-gaap Class Of Warrant Or Right Outstanding
ClassOfWarrantOrRightOutstanding
2147778
CY2021Q4 us-gaap Class Of Warrant Or Right Outstanding
ClassOfWarrantOrRightOutstanding
2204747
CY2023Q1 gnpx Class Of Warrant Or Right Issued In Period
ClassOfWarrantOrRightIssuedInPeriod
3839524
CY2023Q1 gnpx Class Of Warrant Or Right Issued During Period Exercise Price
ClassOfWarrantOrRightIssuedDuringPeriodExercisePrice
1.10
CY2022Q1 gnpx Class Of Warrant Or Right Issued In Period
ClassOfWarrantOrRightIssuedInPeriod
CY2022Q1 gnpx Class Of Warrant Or Right Issued During Period Exercise Price
ClassOfWarrantOrRightIssuedDuringPeriodExercisePrice
CY2023Q1 gnpx Class Of Warrant Or Right Exercised During Period
ClassOfWarrantOrRightExercisedDuringPeriod
38400
CY2023Q1 gnpx Class Of Warrant Or Right Exercised During Period Exercise Price
ClassOfWarrantOrRightExercisedDuringPeriodExercisePrice
6.25
CY2022Q1 gnpx Class Of Warrant Or Right Exercised During Period
ClassOfWarrantOrRightExercisedDuringPeriod
CY2022Q1 gnpx Class Of Warrant Or Right Exercised During Period Exercise Price
ClassOfWarrantOrRightExercisedDuringPeriodExercisePrice
CY2023Q1 us-gaap Class Of Warrant Or Right Outstanding
ClassOfWarrantOrRightOutstanding
5948902
CY2022Q1 us-gaap Class Of Warrant Or Right Outstanding
ClassOfWarrantOrRightOutstanding
2204747
CY2023Q2 gnpx Class Of Warrant Or Right Exercised During Period
ClassOfWarrantOrRightExercisedDuringPeriod
CY2023Q2 gnpx Class Of Warrant Or Right Exercised During Period Exercise Price
ClassOfWarrantOrRightExercisedDuringPeriodExercisePrice
CY2022Q2 gnpx Class Of Warrant Or Right Exercised During Period
ClassOfWarrantOrRightExercisedDuringPeriod
13643
CY2022Q2 gnpx Class Of Warrant Or Right Exercised During Period Exercise Price
ClassOfWarrantOrRightExercisedDuringPeriodExercisePrice
0.50
CY2023Q2 gnpx Class Of Warrant Or Right Cancelled During Period
ClassOfWarrantOrRightCancelledDuringPeriod
CY2023Q2 gnpx Class Of Warrant Or Right Cancelled During Period Exercise Price
ClassOfWarrantOrRightCancelledDuringPeriodExercisePrice
CY2022Q2 gnpx Class Of Warrant Or Right Cancelled During Period
ClassOfWarrantOrRightCancelledDuringPeriod
112993
CY2022Q2 gnpx Class Of Warrant Or Right Cancelled During Period Exercise Price
ClassOfWarrantOrRightCancelledDuringPeriodExercisePrice
4.47
CY2023Q2 us-gaap Class Of Warrant Or Right Outstanding
ClassOfWarrantOrRightOutstanding
5948902
CY2022Q2 us-gaap Class Of Warrant Or Right Outstanding
ClassOfWarrantOrRightOutstanding
2078111
CY2023Q2 gnpx Class Of Warrant Or Right Vested Or Expected To Vest
ClassOfWarrantOrRightVestedOrExpectedToVest
22500
CY2023Q2 gnpx Class Of Warrant Or Right Vested Or Expected To Vest Weighted Average Exercise Price
ClassOfWarrantOrRightVestedOrExpectedToVestWeightedAverageExercisePrice
1.50
CY2022Q2 gnpx Class Of Warrant Or Right Vested Or Expected To Vest
ClassOfWarrantOrRightVestedOrExpectedToVest
CY2022Q2 gnpx Class Of Warrant Or Right Vested Or Expected To Vest Weighted Average Exercise Price
ClassOfWarrantOrRightVestedOrExpectedToVestWeightedAverageExercisePrice
CY2023Q2 gnpx Class Of Warrant Or Right Exercisable
ClassOfWarrantOrRightExercisable
5728069
CY2022Q2 gnpx Class Of Warrant Or Right Exercisable
ClassOfWarrantOrRightExercisable
1844776
gnpx Stock Issued During Period Shares Exercise Of Cashless Warrants
StockIssuedDuringPeriodSharesExerciseOfCashlessWarrants
13643
CY2023Q2 us-gaap Class Of Warrant Or Right Number Of Securities Called By Warrants Or Rights
ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
5948902
gnpx Class Of Warrant Or Right Vesting Period
ClassOfWarrantOrRightVestingPeriod
P12M
CY2023Q2 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
P0Y
CY2023Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
0 pure
CY2023Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
0.0000 pure
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
0.8314 pure
CY2023Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0 pure
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0 pure
CY2023Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
11504327
CY2023Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
47500
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
130000
CY2022Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
11374327
CY2021Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
8574301
CY2023Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
82500
CY2023Q1 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
1.43
CY2022Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
2404562
CY2022Q1 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
2.30
CY2023Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod
CY2023Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice
CY2022Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod
17500
CY2022Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice
2.00
CY2023Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
11456827
CY2022Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
10961363
CY2023Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
47500
CY2023Q2 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
0.85
CY2022Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
487604
CY2022Q2 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
1.59
CY2023Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
11504327
CY2022Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
11448967
CY2023Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber
582981
CY2023Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice
2.02
CY2022Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber
235465
CY2022Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice
3.32
CY2023Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
8722617
CY2022Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
6166620
CY2022Q4 us-gaap Other Commitment
OtherCommitment
340000 usd

Files In Submission

Name View Source Status
0001437749-23-024247-index-headers.html Edgar Link pending
0001437749-23-024247-index.html Edgar Link pending
0001437749-23-024247.txt Edgar Link pending
0001437749-23-024247-xbrl.zip Edgar Link pending
ex_531768.htm Edgar Link pending
ex_531769.htm Edgar Link pending
ex_531770.htm Edgar Link pending
Financial_Report.xlsx Edgar Link pending
gnpx-20230630.xsd Edgar Link pending
gnpx20230630_10q.htm Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R3.htm Edgar Link pending
R4.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
gnpx-20230630_cal.xml Edgar Link unprocessable
gnpx-20230630_lab.xml Edgar Link unprocessable
gnpx-20230630_pre.xml Edgar Link unprocessable
gnpx-20230630_def.xml Edgar Link unprocessable
gnpx20230630_10q_htm.xml Edgar Link completed